JP2013537228A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537228A5
JP2013537228A5 JP2013529184A JP2013529184A JP2013537228A5 JP 2013537228 A5 JP2013537228 A5 JP 2013537228A5 JP 2013529184 A JP2013529184 A JP 2013529184A JP 2013529184 A JP2013529184 A JP 2013529184A JP 2013537228 A5 JP2013537228 A5 JP 2013537228A5
Authority
JP
Japan
Prior art keywords
cancer
leukemia
pharmaceutically acceptable
combination according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013529184A
Other languages
English (en)
Japanese (ja)
Other versions
JP6185839B2 (ja
JP2013537228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/050302 external-priority patent/WO2012036919A2/en
Publication of JP2013537228A publication Critical patent/JP2013537228A/ja
Publication of JP2013537228A5 publication Critical patent/JP2013537228A5/ja
Application granted granted Critical
Publication of JP6185839B2 publication Critical patent/JP6185839B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013529184A 2010-09-14 2011-09-02 Braf阻害薬とvegf阻害薬との組み合わせ Expired - Fee Related JP6185839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38251110P 2010-09-14 2010-09-14
US61/382,511 2010-09-14
PCT/US2011/050302 WO2012036919A2 (en) 2010-09-14 2011-09-02 Combination of braf and vegf inhibitors

Publications (3)

Publication Number Publication Date
JP2013537228A JP2013537228A (ja) 2013-09-30
JP2013537228A5 true JP2013537228A5 (enExample) 2014-09-25
JP6185839B2 JP6185839B2 (ja) 2017-08-23

Family

ID=45832170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529184A Expired - Fee Related JP6185839B2 (ja) 2010-09-14 2011-09-02 Braf阻害薬とvegf阻害薬との組み合わせ

Country Status (4)

Country Link
US (3) US20130172378A1 (enExample)
EP (1) EP2616057A4 (enExample)
JP (1) JP6185839B2 (enExample)
WO (1) WO2012036919A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092406A2 (en) 2006-02-07 2007-08-16 Ticketmaster Methods and systems for reducing burst usage of a networked computer system
AU2013302320A1 (en) * 2012-08-17 2015-02-26 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
CA2882270A1 (en) * 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
WO2014085373A1 (en) * 2012-11-27 2014-06-05 Glaxosmithkline Llc Combination
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DK1343782T3 (da) * 2000-12-21 2009-08-24 Smithkline Beecham Corp Pyrimidinaminer som angiogenesemodulatorer
US20070208023A1 (en) * 2004-04-16 2007-09-06 Smithkline Beecham Corporation Cancer Treatment Method
MXPA06013250A (es) * 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
AU2007272330A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Similar Documents

Publication Publication Date Title
JP2011126896A5 (enExample)
HRP20161074T1 (hr) Benzoksazolski inhibitori kinaza i postupci njihove upotrebe
JP2013537228A5 (enExample)
ME02663B (me) Derivati benzimidazola kao inhibitori pi3 kinaze
IL257219A (en) Prodrugs of glutamine analogs
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2010001302A5 (enExample)
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
HRP20240503T1 (hr) Diaril makrocikli kao modulatori protein kinaza
JP2013522292A5 (enExample)
JP2012516344A5 (enExample)
JP2019514863A5 (enExample)
JP2007511504A5 (enExample)
JP2010518110A5 (enExample)
JP2014508811A5 (enExample)
RU2010142396A (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1-н-бензимидазол-2-ил] хинолин-2(1н)она
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
JP2015512398A5 (enExample)
DOP2011000185A (es) “COMPUESTO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO)PIRAZIN-2-CARBONITRILO, AMINOPIRAZOL UTIL PARA INHIBIR LA PROTEINA CINASA Chk1”
RU2015119218A (ru) Комбинация
CN110545820A (zh) 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
ME02119B (me) Spojevi korisni za inhibiranje chk1
JP2012526766A5 (enExample)
JP2014507412A5 (enExample)